Development of an anti-IL-12 p40 auto-vaccine: Protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection

European Journal of Immunology

Volumn 34, Issue 12, 2004, Pages 3572-3581

  Uyttenhove, Catherine ^a,b   Arendse, Berenice ^c   Stroobant, Vincent ^a   Brombacher, Frank ^c   Van Snick, Jacques ^a,b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b DE DUVE INSTITUTE   (Belgium)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Autoimmunity; IL 12; Vaccination

Indexed keywords

AUTOANTIBODY; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23; LEISHMANIA VACCINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OVALBUMIN; PEPTIDE DERIVATIVE; PROTEIN P40; PROTEIN SUBUNIT; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; GROWTH INHIBITION; IMMUNIZATION; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; INFECTION SENSITIVITY; LEISHMANIA MAJOR; LEISHMANIASIS; MICROBIAL GROWTH; MOUSE; MOUSE STRAIN; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTECTION; STATISTICAL SIGNIFICANCE; TH1 CELL; TH2 CELL; VACCINATION;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P40; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; PROTEIN SUBUNITS; TH2 CELLS; VACCINATION; VACCINES;

EID: 10944221275     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200425443     Document Type: Article

References (47)

1. Dalum, I., Jensen, M. R., Hindersson, P., Elsner, H. I. and Mouritsen, I., Breaking of B cell tolerance toward a highly conserved self protein. J. Immunol. 1996. 157: 4796-4804.
2. Dalum, I., Jensen, M. R., Gregorius, K., Thomasen, K. M., Elsner, H. I. and Mouritsen, S., Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol. Immunol. 1997. 34: 1113-1120.
3. Johnson, H. E., DeAvila, D. M., Chang, C. F. and Reeves, J. J., Active immunization of heifers against luteinizing hormone-releasing hormone, human chorionic gonadotropin and bovine luteinizing hormone. J. Anim. Sci. 1988. 66: 719-726.
4. Talwar, G. P., Singh, O., Pal, R., Chatterjee, N., Sahai, P., Dhall, K., Kaur, J., Das, S. K., Suri, S., Buckshee, K., Saraya, L. and Saxena, B. N., A vaccine that prevents pregnancy in women. Proc. Natl. Acad. Sci. USA 1994. 91: 8532-8536.
5. Ciapponi, L., Maione, D., Scoumanne, A., Costa, P., Hansen, M. B., Svenson, M., Bendtzen, K., Alonzi, T., Paonessa, G., Cortese, R., Ciliberto, G. and Savino, R., Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist. Nat. Biotechnol. 1997. 15: 997-1001.
6. Gringeri, A., Santagostino, E., Cusini, M., Muca-Perja, M., Marinoni, A., Mannucci, P. M., Burny, A., Criscuolo, M., Lu, W., Andrieru, J. M. et al., Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996. 13: 55-67.
7. Dalum, I., Butler, D. M., Jensen, M. R., Hindersson, P., Steinaa, L., Waterston, A. M., Grell, S. N., Feldmann, M., Elsner, H. I. and Mouritsen, S., Therapeutic antibodies elicited by immunization against TNF-alpha. Nat. Biotechnol. 1999. 17: 666-669.
8. Richard, M., Grencis, R. K., Humphreys, N. E., Renauld, J.-C. and Van Snick, J., Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc. Natl. Acad. Sci. USA 2000. 97: 767-772.
9. Svenson, M., Hansen, M. H., Thomsen, A. R., Diamant, M., Nansen, A., Rieneck, K., Otterness, I. G. and Bendtzen, K., Cytokine vaccination: neutralising IL-1alpha autoantibodies induced by immunisation with homologous IL-1alpha. J. Immunol. Methods 2000. 236: 1-8.
10. Khan, W. I., Richard, M., Akiho, H., Blennerhasset, P. A., Humphreys, N. E., Grencis, R. K., Van Snick, J. and Collins, S. M., Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. Infect. Immun. 2003. 71: 2430-2438.
11. Hertz, M., Mahalingam, S., Dalum, I., Klysner, S., Mattes, J., Neisig, A., Mouritsen, S., Foster, P. S. and Gautam, A., Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J. Immunol. 2001. 167: 3792-3799.
12. Chackerian, B., Lowy, D. R. and Schiller, J. T., Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 2001. 108: 415-423.
13. Matthys, P., Vermeire, K., Mitera, T., Heremans, H., Huang, S. and Billiau, A., Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur. J. Immunol. 1998. 28: 2143-2151.
14. McIntyre, K. W., Shuster, D. J., Gillooly, K. M., Warrier, R. R., Connaughton, S. E., Hall, L. B., Arp, L. H., Gately, M. K. and Magram, J., Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur. J. Immunol. 1996. 26: 2933-2938.
15. Hong, K., Chu, A., Ludviksson, B. R., Berg, E. L. and Ehrhardt, R. O., IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 1999. 162: 7480-7491.
16. Huang, F. P., Feng, G. J., Lindop, G., Stott, D. I. and Liew, F. Y., The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRLMP-lprlpr mice. J. Exp. Med. 1996. 183: 1447-1459.
17. Neurath, M. F., Fuss, I., Kelsall, B. L., Stuber, E. and Strober, W., Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 1995. 182: 1281-1290.
18. Nielsen, O. H., Kirman, I., Rudiger, N., Handel, J. and Vainer, B., Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 2003. 38: 180-185.
19. Comabella, M., Balashov, K., Issazadeh, S., Smith, D., Weiner, H. L. and Khoury, S. J., Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest. 1998. 102: 671-678.
20. + T cells via CD40 ligand. Proc. Natl. Acad. Sci. USA 1997. 94: 599-603.
21. Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T. et al., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003. 421: 744-748.
22. Becher, B., Durell, B. G. and Noelle, R. J., Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 2002. 110: 493-497.
23. Heremans, H., Dillen, C., Groenen, M., Matthys, P. and Billiau, A., Role of endogenous interleukin-12 (IL-12) in induced and spontaneous relapses of experimental autoimmune encephalomyelitis in mice. Eur. Cytokine Netw. 1999. 10: 171-180.
24. Constantinescu, C. S., Wysocka, M., Hilliard, B., Ventura, E. S., Lavi, E., Trinchieri, G. and Rostami, A., Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J. Immunol. 1998. 161: 5097-5104.
25. Gately, M. K., Warrier, R. R., Honasoge, S., Carvajal, D. M., Faherty, D. A., Connaughton, S. E., Anderson, T. D., Sarmiento, U., Hubbard, B. R. and Murphy, M., Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int. Immunol. 1994. 6: 157-167.
26. Richard, M., Anti-Interleukin-9 vaccination: a new tool to dissect IL-9 activities in vivo.PhD thesis, U.C.L, Brussels, Belgium. 2002
27. Mattner, F., Magram, J., Ferrante, J., Launois, P., Di Padova, K., Behin, R., Gately, M. K., Louis, J. A. and Alber, G., Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur. J. Immunol. 1996. 26: 1553-1559.
28. Baert, F., Noman, M., Vermeire, S., Van Assche, G., D'Haens, G., Carbonez, A. and Rutgeerts, P., Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003. 348: 601-608.
29. Su, C. G. and Lichtenstein, G. R., Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Gastroenterology 2003. 125: 1544-1546.
30. Tripp, C. S., Gately, M. K., Hakimi, J., Ling, P. and Unanue, E. R., Neutralization of IL-12 decreases resistance to Listeria in SCID and C.B-17 mice. Reversal by IFN-gamma. J. Immunol. 1994. 152: 1883-1887.
31. Castro, A. G., Silva, R. A. and Appelberg, R., Endogenously produced IL-12 is required for the induction of protective T cells during Mycobacterium avium infections in mice. J. Immunol. 1995. 155: 2013-2019.
32. Cooper, A. M., Roberts, A. D., Rhoades, E. R., Callahan, J. E., Getzy, D. M. and Orme, I. M., The role of interleukin-12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995. 84: 423-432.
33. Scharton-Kersten, T. M., Yap, G., Magram, J. and Sher, A., Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J. Exp. Med. 1997. 185: 1261-1273.
34. Fieschi, C., Dupuis, S., Catherinot, E., Feinberg, J., Bustamante, J., Breiman, A., Altare, F., Baretto, R., Le Deist, F., Kayal, S. et al., Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J. Exp. Med. 2003. 197: 527-535.
35. Tozawa, K., Hanai, H., Sugimoto, K., Baba, S., Sugimura, H., Aoshi, T., Uchijima, M., Nagata, T. and Koide, Y., Evidence for the critical role of interleukin-12 but not interferon-gamma in the pathogenesis of experimental colitis in mice. J. Gastroenterol. Hepatol. 2003. 18: 578-587.
36. Uyemura, K., Demer, L. L., Castle, S. C., Jullien, D., Berliner, J. A., Gately, M. K., Warrier, R. R., Pham, N., Fogelman, A. M. and Modlin, R. L., Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J. Clin. Invest. 1996. 97: 2130-2138.
37. Lee, T. S., Yen, H. C., Pan, C. C. and Chau, L. Y., The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 1999. 19: 734-742.
38. Fallarino, F., Uyttenhove, C., Boon, T. and Gajewski, T. F., Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 1996. 156: 1095-1100.
39. Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., Sette, A. et al., Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994. 1: 751-761.
40. Schoenhaut, D. S., Chua, A. O., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., McComas, W., Familletti, P. C., Gately, M. K. and Gubler, U., Cloning and expression of murine IL-12. J. Immunol. 1992. 148: 3433-3440.
41. Weinberg, A. D., Wegmann, K. W., Funatake, C. and Whitham, R. H., Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 1999. 162: 1818-1826.
42. Slavin, A., Ewing, C., Liu, J., Ichikawa, M., Slavin, J. and Bernard, C. C., Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 1998. 28: 109-120.
43. Uyttenhove, C., Simpson, R. and Van Snick, J., Functional and structural characterization of P40, a mouse glycoprotein with T cell growth factor activity. Proc. Natl. Acad. Sci. USA 1988. 85: 6934-6938.
44. Espevik, T. and Nissen-Meyer, J., A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 1986. 95: 99-105.
45. Mohrs, M., Ledermann, B., Kohler, G., Dorfmuller, A., Gessner, A. and Brombacher, F., Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J. Immunol. 1999. 162: 7302-7308.
46. Holscher, C., Kohler, G., Muller, U., Mossmann, H., Schaub, G. A. and Brombacher, F., Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect. Immun. 1998. 66: 1208-1215.
47. Corraliza, I. M., Campo, M. L., Soler, G. and Modolell, M., Determination of arginase activity in macrophages: a micro-method. J. Immunol. Methods 1994. 174: 231-235.